Lomustine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Lomustine" in English language version.

refsWebsite
Global rank English rank
4th place
4th place
2nd place
2nd place
11th place
8th place
low place
low place
1,610th place
1,279th place
102nd place
76th place
5th place
5th place
3,984th place
2,622nd place
low place
low place
low place
low place
447th place
338th place
8,489th place
6,122nd place
low place
low place
low place
low place
719th place
636th place
low place
low place
2,020th place
1,872nd place
5,893rd place
3,320th place
low place
low place
low place
low place
low place
low place
low place
low place

accesswire.com (Global: low place; English: low place)

bccancer.bc.ca (Global: low place; English: low place)

cancerletter.com (Global: low place; English: low place)

cancerresearchuk.org (Global: 8,489th place; English: 6,122nd place)

  • "Lomustine". www.cancerresearchuk.org. Retrieved 2023-05-22.

chemocare.com (Global: low place; English: low place)

doi.org (Global: 2nd place; English: 2nd place)

  • Lee FY, Workman P, Roberts JT, Bleehen NM (1985). "Clinical pharmacokinetics of oral CCNU (lomustine)". Cancer Chemotherapy and Pharmacology. 14 (2): 125–131. doi:10.1007/bf00434350. PMID 3971475. S2CID 29619378.
  • Wirsching HG, Tritschler I, Palla A, Renner C, Weller M, Tabatabai G (December 2014). "The management of lomustine overdose in malignant glioma patients". Neuro-Oncology Practice. 1 (4): 178–183. doi:10.1093/nop/npu023. PMC 4369719. PMID 26034630.
  • Diab S, Raiyat M, Gerogiorgis DI (2021). "Flow synthesis kinetics for lomustine, an anti-cancer active pharmaceutical ingredient". Reaction Chemistry & Engineering. 6 (10): 1819–1828. doi:10.1039/D1RE00184A. hdl:20.500.11820/7466f1c6-1f4d-402c-a53e-d4d40f73f3ff. ISSN 2058-9883. S2CID 237643008.
  • Jaman Z, Sobreira TJ, Mufti A, Ferreira CR, Cooks RG, Thompson DH (February 2019). "Rapid on-demand synthesis of lomustine under continuous flow conditions". Organic Process Research & Development. 23 (3): 334–341. doi:10.1021/acs.oprd.8b00387.s001.
  • Temerk Y, Ibrahim M, Ibrahim H, Kotb M (2016-05-15). "Interactions of an anticancer drug lomustine with single and double stranded DNA at physiological conditions analyzed by electrochemical and spectroscopic methods". Journal of Electroanalytical Chemistry. 769: 62–71. doi:10.1016/j.jelechem.2016.03.020. ISSN 1572-6657.
  • Weller M, Le Rhun E (July 2020). "How did lomustine become standard of care in recurrent glioblastoma?". Cancer Treatment Reviews. 87 102029. doi:10.1016/j.ctrv.2020.102029. hdl:20.500.12210/75164. PMID 32408220. S2CID 218648915.
  • Fisher JP, Adamson DC (March 2021). "Current FDA-Approved Therapies for High-Grade Malignant Gliomas". Biomedicines. 9 (3): 324. doi:10.3390/biomedicines9030324. PMC 8004675. PMID 33810154.

drugbank.com (Global: low place; English: low place)

go.drugbank.com

empr.com (Global: low place; English: low place)

fda.gov (Global: 447th place; English: 338th place)

accessdata.fda.gov

figshare.com (Global: 5,893rd place; English: 3,320th place)

gleostine.com (Global: low place; English: low place)

handle.net (Global: 102nd place; English: 76th place)

hdl.handle.net

mayoclinic.org (Global: 1,610th place; English: 1,279th place)

medscape.com (Global: 719th place; English: 636th place)

reference.medscape.com

nextsourcebiotechnology.com (Global: low place; English: low place)

nih.gov (Global: 4th place; English: 4th place)

pubmed.ncbi.nlm.nih.gov

  • Lee FY, Workman P, Roberts JT, Bleehen NM (1985). "Clinical pharmacokinetics of oral CCNU (lomustine)". Cancer Chemotherapy and Pharmacology. 14 (2): 125–131. doi:10.1007/bf00434350. PMID 3971475. S2CID 29619378.
  • Hay JK, Larson VS (December 2019). "Lomustine (CCNU) and prednisone chemotherapy for high-grade completely excised canine mast cell tumors". The Canadian Veterinary Journal. 60 (12): 1326–1330. PMC 6855235. PMID 31814640.
  • Wirsching HG, Tritschler I, Palla A, Renner C, Weller M, Tabatabai G (December 2014). "The management of lomustine overdose in malignant glioma patients". Neuro-Oncology Practice. 1 (4): 178–183. doi:10.1093/nop/npu023. PMC 4369719. PMID 26034630.
  • Weller M, Le Rhun E (July 2020). "How did lomustine become standard of care in recurrent glioblastoma?". Cancer Treatment Reviews. 87 102029. doi:10.1016/j.ctrv.2020.102029. hdl:20.500.12210/75164. PMID 32408220. S2CID 218648915.
  • Fisher JP, Adamson DC (March 2021). "Current FDA-Approved Therapies for High-Grade Malignant Gliomas". Biomedicines. 9 (3): 324. doi:10.3390/biomedicines9030324. PMC 8004675. PMID 33810154.

ncbi.nlm.nih.gov

rsc.org (Global: 2,020th place; English: 1,872nd place)

xlink.rsc.org

semanticscholar.org (Global: 11th place; English: 8th place)

api.semanticscholar.org

  • Lee FY, Workman P, Roberts JT, Bleehen NM (1985). "Clinical pharmacokinetics of oral CCNU (lomustine)". Cancer Chemotherapy and Pharmacology. 14 (2): 125–131. doi:10.1007/bf00434350. PMID 3971475. S2CID 29619378.
  • Diab S, Raiyat M, Gerogiorgis DI (2021). "Flow synthesis kinetics for lomustine, an anti-cancer active pharmaceutical ingredient". Reaction Chemistry & Engineering. 6 (10): 1819–1828. doi:10.1039/D1RE00184A. hdl:20.500.11820/7466f1c6-1f4d-402c-a53e-d4d40f73f3ff. ISSN 2058-9883. S2CID 237643008.
  • Weller M, Le Rhun E (July 2020). "How did lomustine become standard of care in recurrent glioblastoma?". Cancer Treatment Reviews. 87 102029. doi:10.1016/j.ctrv.2020.102029. hdl:20.500.12210/75164. PMID 32408220. S2CID 218648915.

tga.gov.au (Global: 3,984th place; English: 2,622nd place)

ebs.tga.gov.au

vcahospitals.com (Global: low place; English: low place)

wedgewoodpharmacy.com (Global: low place; English: low place)

worldcat.org (Global: 5th place; English: 5th place)

search.worldcat.org